by TractManager | Apr 12, 2021 | Emerging Technology Report
Oxlumo (lumasiran) is a subcutaneously injected, HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Dosing is weight-based; for...
by TractManager | Apr 7, 2021 | Molecular Test Assessment
This report evaluates the analytical validity, clinical validity, and clinical utility of the Afirma Genomic Sequencing Classifier (Veracyte Inc.) test.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Apr 6, 2021 | Health Technology Assessment
Focus of the Report: This report focuses on pattern electroretinography (PERG) for the diagnosis of glaucoma.Technology Description: Early diagnosis of glaucoma can reduce the risk of irreversible vision loss and blindness. Electroretinography (ERG) is a minimally...
by TractManager | Mar 31, 2021 | News
The Food and Drug Administration (FDA) has issued the following safety alerts:Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast ReconstructionThe FDA is informing patients, caregivers, and health care providers that certain acellular dermal matrix...
by TractManager | Mar 31, 2021 | Emerging Technology Report
The Portable Neuromodulation Stimulator (PoNS) device is a portable neuromodulation stimulator for short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis for use by prescription only as an adjunct to a supervised therapeutic...
Recent Comments